[go: up one dir, main page]

WO2007146311A3 - Compositions and methods for protecting newborn lung development with ethyl nitrite - Google Patents

Compositions and methods for protecting newborn lung development with ethyl nitrite Download PDF

Info

Publication number
WO2007146311A3
WO2007146311A3 PCT/US2007/013826 US2007013826W WO2007146311A3 WO 2007146311 A3 WO2007146311 A3 WO 2007146311A3 US 2007013826 W US2007013826 W US 2007013826W WO 2007146311 A3 WO2007146311 A3 WO 2007146311A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
ethyl nitrite
lung development
hyperoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/013826
Other languages
French (fr)
Other versions
WO2007146311A2 (en
Inventor
Kevin P Hurley
Jonathan S Stamler
Richard L Auten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NITROX LLC
Original Assignee
NITROX LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NITROX LLC filed Critical NITROX LLC
Publication of WO2007146311A2 publication Critical patent/WO2007146311A2/en
Publication of WO2007146311A3 publication Critical patent/WO2007146311A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of diagnosing, treating or preventing hyperoxia-induced lung disease using the compositions of the invention. The present invention also provides methods of reducing hyperoxia-induced lung inflammation, hyperoxia-induced NF-ϰB activation in the lung and hyperoxia-induced cytokine expression in the lung using the compositions of the invention.
PCT/US2007/013826 2006-06-12 2007-06-12 Compositions and methods for protecting newborn lung development with ethyl nitrite Ceased WO2007146311A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81319206P 2006-06-12 2006-06-12
US60/813,192 2006-06-12

Publications (2)

Publication Number Publication Date
WO2007146311A2 WO2007146311A2 (en) 2007-12-21
WO2007146311A3 true WO2007146311A3 (en) 2008-02-21

Family

ID=38832502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/013826 Ceased WO2007146311A2 (en) 2006-06-12 2007-06-12 Compositions and methods for protecting newborn lung development with ethyl nitrite

Country Status (1)

Country Link
WO (1) WO2007146311A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140373836A1 (en) * 2013-06-25 2014-12-25 Ino Therapeutics Llc Methods of Reducing the Risk of Mortality Associated With a Medical Treatment
WO2021217028A1 (en) * 2020-04-23 2021-10-28 University Hospitals - Cleveland Medical Center Compositions and methods for in vivo lung and blood sno repletion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5839433A (en) * 1993-10-12 1998-11-24 Higenbottam; Timothy William Nitric oxide treatment
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5839433A (en) * 1993-10-12 1998-11-24 Higenbottam; Timothy William Nitric oxide treatment
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUTEN ET AL.: "Blocking Leukocyte Influx and Function to Prevent Chronic Lung Disease of Prematurity", PEDIATRIC PULMONOLOGY, vol. 35, 2003, pages 335 - 341 *
DAVIDSON ET AL.: "Reaction of Oxygen Atoms with Methyl and Ethyl Nitrites", UNIVERSITY OF CAMBRIDGE, DEPARTMENT OF PHYSICAL CHEMISTRY, LENSFIELD ROAD, CAMBRIDGE CB2 IEP, 1975, pages 2413 - 2420 *

Also Published As

Publication number Publication date
WO2007146311A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2007044026A3 (en) Compositions comprising modified collagen and uses therefore
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2007061874A3 (en) Methods and compositions for use in treating cancer
EP1835929B8 (en) Anti-kir combination treatments and methods
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
AU2016204344A1 (en) Improved methods and compositions for wound healing
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
WO2007089445A3 (en) Ang2 and vegf inhibitor combinations
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2005097825A3 (en) Bmp-7 variants with improved properties
EP1750754A4 (en) Human glp-1 mimetibodies, compositions, methods and uses
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
WO2007011962A3 (en) Treatment of cancer
ZA200901132B (en) Human GLP-1 mimetibodies, compositions, methods and uses
WO2006015263A3 (en) Lonidamine analogs
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2008030883A3 (en) Treatment of cancer
MX2007001035A (en) Method of producing a composition, composition and its use.
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2007106915A3 (en) Antibodies to egfl7 and methods for their use
PL2410047T3 (en) Oxidoreductase and its use for the reduction of secodione derivatives
AU2006321904A8 (en) 1, 1, 3-trioxo-1 , 2 , 5-thiadiazolidines and their use as PTP-ases inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809507

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07809507

Country of ref document: EP

Kind code of ref document: A2